Premium
Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy
Author(s) -
Choi BoHwa,
Kang HyunKyu,
Park JungSun,
Kim SangKi,
Pham ThanNhan Nguyen,
Zhu XiaoWei,
Cho Duck,
Nam JongHee,
Chung IkJoo,
Kim YoungJin,
Rhee JoonHaeng,
Kim HyeoungJoon,
Lee JeJung
Publication year - 2006
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20105
Subject(s) - cd80 , medicine , immunotherapy , immunology , myeloid leukemia , cd86 , cd8 , myeloid , cytotoxic t cell , cancer research , immune system , t cell , in vitro , cd40 , biology , biochemistry
Abstract Clinical application of immunotherapy for acute myeloid leukemia (AML) requires the efficient induction of dendritic cells (DCs) from AML blast cells using in vitro culture. We examined the effect of autologous serum on the properties of leukemic DCs derived from leukemic cells of AML patients by culture in AIM‐V medium with GM‐CSF, IL‐4, TNF‐α, and 0, 2, 5, or 10% human autologous serum. The expressions of CD80, CD83, CD86, and HLA‐DR were upregulated under all culture conditions; however, 10% autologous serum induced the highest expression levels of several molecules. The capacity of leukemic DCs to stimulate allogeneic T cells increased with increasing serum concentration. Stimulation of autologous CD3+ T cells with leukemic DCs grown in the presence of various concentrations of autologous serum resulted in induction of more IFN‐γ‐secreting cells than was the case for unprimed CD3+ T cells. Leukemic DCs cultured with 10% autologous serum induced the highest numbers of IFN‐γ‐secreting cells and CD8+CD56+ T cells from autologous T cells. These results suggest that culture of AML blast cells in the presence of autologous serum could be used to generate leukemic DCs for immunotherapy against AML. The highest serum concentration appeared optimal for generating the most potent leukemic DCs. J. Clin. Apheresis. © 2006 Wiley‐Liss, Inc.